DARAXONRASIB (RMC-6236)

DRUG5 trials

Sponsors

Revolution Medicines Inc.

Conditions

Lung CancerMetastatic Pancreatic Ductal AdenocarcinomaResected Pancreatic Ductal Adenocarcinoma (PDAC)non-small cell lung cancer

Phase 1

A Phase 1b/2 Open-Label, Multicenter Study of RMC-6236 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B

RecruitingCTIS2023-509572-42-00

Revolution Medicines Inc.Lung Cancer

Start: 2024-07-17Target: 180Updated: 2026-01-13

Phase 2

A Phase 1b/2 Open-Label, Multicenter Study of RMC-9805 with or without RMC-6236, in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C

RecruitingCTIS2025-521147-21-00

Revolution Medicines Inc.Lung Cancer

Start: 2025-10-08Target: 130Updated: 2026-01-14

Phase 3

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Active, not recruitingCTIS2024-516063-89-00

Revolution Medicines Inc.Metastatic Pancreatic Ductal Adenocarcinoma

Start: 2025-04-10Target: 136Updated: 2025-12-08

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS(MUT) NSCLC

RecruitingCTIS2024-518154-16-00

Revolution Medicines Inc.non-small cell lung cancer

Start: 2025-08-27Target: 296Updated: 2026-01-21

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Not yet recruitingCTIS2025-523495-23-00

Revolution Medicines Inc.Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Target: 74Updated: 2026-04-28